N Engl J Med 2025;393:1796-1806 [9] Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial, December 2025: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company [10] Fourth High-level Meeting of the UN General Assembly on the prevention and control of NCDs and the promotion of mental health and wellbeing (HLM4), September 2025: [11] Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study, November 2025: Thousands of patients from Scotlands poorest areas to benefit from landmark UK government-funded obesity study - GOV.UK [12] Non-Traditional Channels: The Compounded GLP-1 Market
PMC 6308032
When both parents are carriers, newborn screening results are not sufficient to rule out CAT deficiency in a newborn baby
doi: 10.1016/j.colsurfb.2014.02.036
Advances in metabolite processing methods and metabolite identification tools, such as Bio-Transformer, are expected to further expand the number of annotated metabolites, enhancing the comprehensive coverage enabled by of metabolic databases (Djoumbou-Feunang et al., 2019
